The 黑料网® (黑料网®) responded to a targeted request for information from U.S. Rep. Ami Bera, MD, (CA-6), a member of the bipartisan House Task Force on Artificial Intelligence (AI), regarding the state of health care artificial intelligence (AI). Rep. Bera’s RFI included an extensive list of questions focused on various aspects of healthcare AI oversight, implementation, use and innovation.
黑料网 highlighted examples of real-world applications of healthcare AI and recommended ways to enhance product transparency and oversight mechanisms moving forward, including leveraging public-private partnerships. The College provided concepts that would be important in any future value-based payment approach looking at ensuring quality implementation, governance and use of high-value AI tools. 黑料网 noted that not all currently reimbursed uses of AI are adding value to patients or the health system.
黑料网 also highlighted novel oversight questions posed by foundation models/generative AI used to enable higher risk functions such as diagnosis or treatment. The College noted the U.S. Food and Drug Administration may benefit from expanded authorities to meet future regulatory challenges and opportunities.
For more information about 黑料网’s AI-related programs and initiatives, visit the . For questions about the 黑料网 comment submission or AI oversight policy, contact Michael Peters, 黑料网 Senior Government Affairs Director.